GlassScriptPhysician profile
Aylin Selek
NPI 1376868414
$3,088.27
in general payments reported to CMS, 2019-2025
21 companies · $590 in 2025
The $590 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2020: $209 · 2021: $298 · 2022: $241 · 2023: $778 · 2024: $858 · 2025: $590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,226.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $645.50 | 2019-2025 | Lokelma, Farxiga |
| Mallinckrodt Hospital Products INC. | $389.70 | 2021-2025 | Terlivaz, Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $268.77 | 2023-2025 | |
| Outset Medical INC | $261.05 | 2023 | |
| Calliditas Therapeutics US INC. | $231.99 | 2022-2024 | Tarpeyo |
| Vifor Pharma, INC. | $200.00 | 2021 | |
| Ani Pharmaceuticals, INC. | $184.17 | 2024-2025 | Purified Cortrophin Gel |
| Ardelyx, INC. | $142.07 | 2024-2025 | Ibsrela |
| Otsuka America Pharmaceutical, INC. | $116.49 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $99.16 | 2024-2025 | |
| Glaxosmithkline, LLC. | $94.01 | 2023 | Jesduvroq, Benlysta |
| Amgen INC. | $88.56 | 2024-2025 | Repatha, Otezla, Otezla |
| Opko Pharmaceuticals, LLC | $69.34 | 2024-2025 | Rayaldee |
| Aurinia Pharma U.S., INC. | $49.25 | 2022-2024 | Lupkynis |
| Akebia Therapeutics INC | $48.31 | 2020-2025 | Vafseo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.66 | 2023 | Xifaxan |
| Novo Nordisk INC | $45.62 | 2024-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $39.04 | 2023-2024 | |
| Alvogen INC | $27.47 | 2023 | Teriparatide |
| Genentech USA, INC. | $21.33 | 2021 | |
| Fresenius USA Marketing, INC. | $19.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aylin Selek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.